![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
https://endpts.com/senate-democrats-question-why-novo-discontinued-its-long-acting-insulin-levemir/
https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-cut-price-insulin-by-up-75-wsj-2023-03-14/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021536
https://www.pharmacompass.com/pdf/news/novo-nordisk-issues-voluntary-nationwide-recall-of-levemir-1620795213.pdf
https://www.biopharmadive.com/news/novo-faces-shareholder-suit-over-insulin-sales-disclosures/561091/
http://www.pmlive.com/pharma_news/novo_nordisk_preps_for_speedy_oral_glp-1_drug_filing_1277020
http://www.pharmatimes.com/news/novo_nordisk_sees_revenues_drop_in_q2_1248067
https://www.fiercepharma.com/pharma/revlimid-and-pomalyst-price-increases-could-celgene-be-next-trump-s-to-call-list
https://www.bloomberg.com/news/articles/2018-07-10/drugmakers-cancel-price-hikes-as-california-law-takes-effect
https://www.fiercepharma.com/marketing/novo-nordisk-s-tresiba-snags-label-boost-highlights-hypo-safety
https://platform.mi.spglobal.com/web/client?auth=inherit#news/article?id=43852931&cdid=A-43852931-11822
http://www.news.sanofi.us/2018-02-01-Toujeo-R-reduced-risk-of-severe-low-blood-sugar-compared-to-insulin-glargine-100-Units-mL-and-insulin-detemir
http://www.pmlive.com/pharma_news/novo_says_real-world_data_backs_its_insulin_switching_1195327
http://www.fiercepharma.com/special-report/top-10-diabetes-drugs-by-2016-sales
http://www.prnewswire.com/news-releases/novo-nordisk-receives-fda-approval-of-tresiba-insulin-degludec-injection-100-uml-200-uml-for-use-in-children-and-adolescents-with-diabetes-300381285.html
http://www.fiercebiotech.com/medical-devices/voluntis-scores-u-s-eu-nods-for-type-2-diabetes-management-software
http://www.wsj.com/articles/drugmakers-find-competition-doesnt-keep-a-lid-on-prices-1480248003
https://www.statnews.com/pharmalot/2016/11/03/sanders-insulin-investigation/
http://www.fiercepharma.com/story/sanofi-patent-deal-lets-lilly-roll-out-lantus-biosim-us-next-december/2015-09-28
http://www.pharmexec.com/restricted-access-essentials-pharma
http://www.fiercepharmamarketing.com/story/will-pricey-new-drug-classes-take-wind-out-diabetes-launches/2015-08-19
http://www.fiercepharma.com/story/pharma-hikes-prices-all-sorts-meds-hit-diabetes-hardest-bloomberg/2015-05-06
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/04/news_detail_002310.jsp&mid=WC0b01ac058004d5c1